How do I know if my Non-Small Cell Lung Cancer has an actionable mutation

Understanding Actionable Mutations in Non-Small Cell Lung Cancer

Great question—this is one of the most important things to understand about your NSCLC diagnosis. Let me explain what actionable mutations are and how you'll know if you have one.

What Is an Actionable Mutation?

An actionable mutation is a specific genetic change in your cancer cells that doctors can target with specialized drugs called targeted therapies. Think of it like this: instead of using chemotherapy that attacks all rapidly dividing cells, targeted therapies are designed to attack cancer cells with specific genetic "weak spots."

According to the NCCN Guidelines for Non-Small Cell Lung Cancer (Version 8.2025), there are several well-established actionable mutations that oncologists routinely test for:

The Main Actionable Mutations:

1. EGFR mutations (Epidermal Growth Factor Receptor)

   • Most common actionable mutation
   • Responds to drugs like osimertinib

2. ALK rearrangements (Anaplastic Lymphoma Kinase)

   • Responds to drugs like alectinib, brigatinib, or lorlatinib

3. ROS1 rearrangements

   • Responds to targeted therapies

4. BRAF mutations (specifically p.V600E)

   • Responds to combination therapy with dabrafenib plus trametinib

5. KRAS mutations (particularly G12C)

   • Newer options: sotorasib or adagrasib

6. METex14 skipping mutations (MET exon 14)

   • Occurs in 3-4% of adenocarcinoma cases

7. ERBB2/HER2 mutations

   • Responds to fam-trastuzumab deruxtecan-nxki

8. NTRK fusions (Neurotrophic Tyrosine Receptor Kinase)

9. RET rearrangements

---

How You'll Know If You Have an Actionable Mutation

Step 1: Biomarker Testing

Your oncologist should order molecular testing (also called biomarker testing) on your tumor tissue or blood sample. According to NCCN Guidelines, this testing should happen when:

• You're diagnosed with metastatic (advanced) NSCLC
• Your cancer is nonsquamous (adenocarcinoma or NOS - "not otherwise specified")
• Even some squamous cell carcinomas should be tested

Step 2: Testing Methods

The lab will use one of these approaches:

• NGS (Next-Generation Sequencing) — the most comprehensive method that can detect multiple mutations at once
• Real-time PCR — targets specific mutations
• Tissue or blood (liquid biopsy) — both can be used

Step 3: Your Results Report

Your pathology report will show:

• Which mutations were found (if any)
• Which mutations were NOT found (negative results are also important)
• The specific type of mutation (this matters because different EGFR mutations respond to different drugs, for example)

---

What If You Have Multiple Mutations?

According to NCCN Guidelines, most actionable mutations don't overlap—meaning you typically have one driver mutation, not several. However, 1-3% of NSCLC cases may have concurrent alterations, and some mutations can occur together (like METex14 skipping and MET amplification).

---

Important Clinical Context: Why This Matters

If you have an actionable mutation:

• Your doctor will likely recommend targeted therapy FIRST, before chemotherapy
• Targeted therapies often have fewer side effects than traditional chemotherapy
• Response rates are typically higher than chemotherapy alone

If you DON'T have an actionable mutation:

• You may be treated with immunotherapy (checkpoint inhibitors) or chemotherapy
• Your doctor will check your PD-L1 expression level to help guide treatment decisions

---

Questions to Ask Your Oncologist

1. "Has my tumor been tested for actionable mutations? If so, what were the results?"

   • If not tested: "Why not, and when will testing happen?"

2. "Which specific mutations was my tumor tested for?"

   • This ensures comprehensive testing was done

3. "If I have an actionable mutation, what targeted therapy do you recommend, and why?"

4. "What is my PD-L1 expression level, and what does that mean for my treatment?"

5. "Can I see a copy of my pathology report and molecular testing results?"

   • You have the right to your [ID removed]

6. "Are there any clinical trials available for my specific mutation?"

---

Getting Your Results

According to NCCN Guidelines, testing should be performed at properly accredited laboratories (minimum CLIA accreditation). Your oncologist's office should provide you with:

• A written report of results
• An explanation of what the findings mean
• Recommendations for treatment based on those results

If you haven't received detailed results yet, ask your care team for a copy of your molecular testing report—you're entitled to this information.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.